



This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the administration or supply of

Combined Transdermal Patch (EVRA[®])

By registered health care professionals for

Contraception

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

PGD NUMBER 82

1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021

2. Medicines practice guideline 2: *Patient group directions*

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care [PGD website FAQs](#)

3. PGD development

Refer to the [NICE PGD competency framework for people developing PGDs](#)

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

4. PGD authorisation

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

5. PGD adoption by the provider

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job title and organisation	Signature	Date	Applicable or not applicable to area

6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the [NICE PGD competency framework for health professionals using PGDs](#)

	Requirements of registered Healthcare professionals working under the PGD
Qualifications and professional registration	<ul style="list-style-type: none"> Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy Pharmacists must be practising in Manx Care authorised premises i.e. contracted pharmacy premises Specific training in sexual health and/or contraception, or equivalent experience
Initial training	<ul style="list-style-type: none"> Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD Local training in the use of PGDs
Competency assessment	Staff will be assessed on their knowledge of drugs and clinical assessment as part the competency framework for registered health professionals using PGDs
Ongoing training and competency	The registered health care professionals should make sure they are aware of any changes to the recommendations for this medication; it is the responsibility of the registered health care professionals to keep up to date with continuing professional development. PGD updates will be held every two years

7. Clinical Conditions

Clinical condition or situation to which this PGD applies	Contraception
Inclusion criteria	Females of childbearing potential
Exclusion criteria	<ul style="list-style-type: none"> • Any UKMEC level 3 or 4 • Anyone with 2 or more UKMEC level 2s • Anyone to be judged not to be Fraser Competent
Cautions (including any relevant action to be taken)	<ul style="list-style-type: none"> • Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration) – seek specialist advice • Crohn's disease • Gene mutations associated with breast cancer (e.g. BRCA 1) • History of severe depression especially if induced by hormonal contraceptive • Hyperprolactinaemia (seek specialist advice) • Inflammatory bowel disease • Migraine • Personal or family history of hypertriglyceridaemia (increased risk of pancreatitis) • Risk factors for arterial disease • Risk factors for venous thromboembolism • Sickle-cell disease • Undiagnosed breast mass
Arrangements for referral for medical advice	Patient should be referred to a more experienced clinical practitioner for further assessment
Action to be taken if patient excluded	Patient should be referred to a more experienced clinical practitioner for further assessment
Action to be taken if patient declines treatment	<ul style="list-style-type: none"> • A verbal explanation should be given to the patient on: the need for the medication and any possible effects or potential risks which may occur as a result of refusing treatment • This information must be documented in the patients' health records • Any patient who declines care must have demonstrated capacity to do so • Where appropriate care should be escalated

8. Details of the medicine

Name, form and strength of medicine	Ethinylestradiol 600mcg/Norelgestromin 6mg transdermal patch (releases 33.9 micrograms of Ethinylestradiol and 203 micrograms of Norelgestromin per 24 hours)
Legal category	Prescription Only Medication (POM)
Indicate any <u>off-label use</u> (if relevant)	Quick start method/Tailored regimes
Route/method of administration	Transdermal

Dose and frequency	Apply 1 patch once weekly for 3 weeks, apply first patch on day 1 of cycle, change patch on days 8 and 15; remove third patch on day 22 and apply new patch after 7-day patch-free interval to start subsequent contraceptive cycle, subsequent courses repeated after a 7-day patch free interval (during which withdrawal bleeding occurs)
Quantity to be administered supplied	<ul style="list-style-type: none"> • 9 patches for a 3 month supply to • 36 patches for a 12 month supply
Maximum or minimum treatment period	Maximum 12 months/for one episode of care
Storage	Room temperature in locked cupboard
Adverse effects	<ul style="list-style-type: none"> • Acne • Alopecia • Headaches • Metrorrhagia • Hypertension • Nausea • Fluid retention • Weight increased
Records to be kept	The administration of any medication given under a PGD must be recorded within the patient's medical records

9. Patient information

Verbal/Written information to be given to patient or carer	<ul style="list-style-type: none"> • Verbal information must be given to patients and or carers for all medication being administered under a PGD • Where medication is being supplied under a PGD, written patient information leaflet must also be supplied • A patient information leaflet is available on request
Follow-up advice to be given to patient or carer	If symptoms do not improve or worsen or you become unwell, seek medical advice immediately

10. Appendix A

References
1. British National Formulary (BNF) available online: https://bnf.nice.org.uk
2. Nursing and Midwifery (2018) "The code" available online: https://www.nmc.org.uk
3. Current Health Care Professions Council standards of practice
4. General Pharmaceutical Council standards
5. The General Optical Council
6. Electronic medicines compendium available online: https://www.medicines.org.uk
7. Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit Guidance for Injectable Progestones (CEU GUIDANCE)
8. Faculty of Sexual and Reproductive Healthcare UK Medical Eligibility Criteria Document (UK MEC)
9. Family Planning Clinic Safeguarding Risk Assessment Tool

11. Appendix B

Health professionals agreed to practice

- Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor
- A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves